1	Hombre	hombre	NCMS000	C0025266#C0086418#C0043210	persona#organismo_vivo	0-6	389_QUEST_clinical_caseMIR	SENT1	-	-
2	de	de	SPS00	C0332285	atributo	7-9	389_QUEST_clinical_caseMIR	SENT1	-	-
3	60	60		-	-	10-12	389_QUEST_clinical_caseMIR	SENT1	-	-
4	años	año	NCMP000	C0439234	calificador	13-17	389_QUEST_clinical_caseMIR	SENT1	-	-
5	que	que	PR0CN000	-	-	18-21	389_QUEST_clinical_caseMIR	SENT1	-	-
6	sufrió	sufrir	VMIS3S0	-	-	22-28	389_QUEST_clinical_caseMIR	SENT1	-	-
7	un	un		C0205447_1	calificador_1	29-31	389_QUEST_clinical_caseMIR	SENT1	-	-
8	infarto	infarto	NCMS000	C0027051_1	trastorno_1	32-39	389_QUEST_clinical_caseMIR	SENT1	B-Grp_Enfermedad	-
9	de	de	SPS00	C0027051_2	trastorno_2	40-42	389_QUEST_clinical_caseMIR	SENT1	-	-
10	miocardio	miocardio	NCMS000	C0027051_3	trastorno_3	43-52	389_QUEST_clinical_caseMIR	SENT1	B-Estructura_Corporal	-
11	hace	hacer	VMIP3S0	-	-	53-57	389_QUEST_clinical_caseMIR	SENT1	-	-
12	1	1		-	-	58-59	389_QUEST_clinical_caseMIR	SENT1	-	-
13	año	año	NCMS000	C0439234	calificador	60-63	389_QUEST_clinical_caseMIR	SENT1	-	-
14	.	.	Fp	-	-	63-64	389_QUEST_clinical_caseMIR	SENT1	-	-

1	Se	se	P00CN000	-	-	65-67	389_QUEST_clinical_caseMIR	SENT2	-	-
2	lo	lo	PP3CNA00	-	-	68-70	389_QUEST_clinical_caseMIR	SENT2	-	-
3	remiten	remitir	VMIP3P0	C0439600	calificador	71-78	389_QUEST_clinical_caseMIR	SENT2	-	-
4	para	para	SPS00	C0521125	calificador	79-83	389_QUEST_clinical_caseMIR	SENT2	-	-
5	valorar	valorar	VMN0000	-	-	84-91	389_QUEST_clinical_caseMIR	SENT2	-	-
6	su	su	DP3CS0	-	-	92-94	389_QUEST_clinical_caseMIR	SENT2	-	-
7	tratamiento	tratamiento	NCMS000	C1273870#C0087111	procedimiento#régimen/tratamiento	95-106	389_QUEST_clinical_caseMIR	SENT2	-	-
8	.	.	Fp	-	-	106-107	389_QUEST_clinical_caseMIR	SENT2	-	-

1	Está	estar	VAM02S0	-	-	108-112	389_QUEST_clinical_caseMIR	SENT3	-	-
2	tomando	tomar	VMG0000	C1515187	calificador	113-120	389_QUEST_clinical_caseMIR	SENT3	-	-
3	gemfibrozilo	gemfibrozilo	NC00SC0	C0017245	sustancia	121-133	389_QUEST_clinical_caseMIR	SENT3	B-Grp_Medicamento	-
4	900	900	Z	-	-	134-137	389_QUEST_clinical_caseMIR	SENT3	-	-
5	mg	mg	NCMN000	-	-	138-140	389_QUEST_clinical_caseMIR	SENT3	-	-
6	,	,	Fc	-	-	140-141	389_QUEST_clinical_caseMIR	SENT3	-	-
7	lisinopríl	lisinopríl	AQ0CS00	-	-	142-152	389_QUEST_clinical_caseMIR	SENT3	B-Grp_Medicamento	-
8	20	20	Z	-	-	153-155	389_QUEST_clinical_caseMIR	SENT3	-	-
9	mg	mg	NCMN000	-	-	156-158	389_QUEST_clinical_caseMIR	SENT3	-	-
10	,	,	Fc	-	-	158-159	389_QUEST_clinical_caseMIR	SENT3	-	-
11	aspirina	aspirina	NCFS000	C0004057	sustancia	160-168	389_QUEST_clinical_caseMIR	SENT3	B-Grp_Medicamento	-
12	100	100	Z	-	-	169-172	389_QUEST_clinical_caseMIR	SENT3	-	-
13	mg	mg	NCMN000	-	-	173-175	389_QUEST_clinical_caseMIR	SENT3	-	-
14	y	y	CC	C1706368	calificador	176-177	389_QUEST_clinical_caseMIR	SENT3	-	-
15	carvedilol	carvedilol	NCMS000	C0054836	producto#sustancia	178-188	389_QUEST_clinical_caseMIR	SENT3	B-Grp_Medicamento	-
16	25	25	Z	-	-	189-191	389_QUEST_clinical_caseMIR	SENT3	-	-
17	mg	mg	NCMN000	-	-	192-194	389_QUEST_clinical_caseMIR	SENT3	-	-
18	.	.	Fp	-	-	194-195	389_QUEST_clinical_caseMIR	SENT3	-	-

1	En	en	SPS00	C1720294#C0332285	calificador#atributo	196-198	389_QUEST_clinical_caseMIR	SENT4	-	-
2	sus	su	DP3CP0	-	-	199-202	389_QUEST_clinical_caseMIR	SENT4	-	-
3	análisis	análisis	NCMN000	C0002778	calificador	203-211	389_QUEST_clinical_caseMIR	SENT4	-	-
4	tiene	tener	VMIP3S0	-	-	212-217	389_QUEST_clinical_caseMIR	SENT4	-	-
5	cLDL	cholesterol_low-density_lipoproteins_(colesterol_de_las_lipoproteínas_de_baja_densidad)	NC00YL0	-	-	218-222	389_QUEST_clinical_caseMIR	SENT4	-	-
6	162	162	Z	-	-	223-226	389_QUEST_clinical_caseMIR	SENT4	-	-
7	mg	mg	NCMN000	-	-	227-229	389_QUEST_clinical_caseMIR	SENT4	-	-
8	/	/	Fh	-	-	229-230	389_QUEST_clinical_caseMIR	SENT4	-	-
9	dL	decilitro	NCMN000	C0439241	calificador	230-232	389_QUEST_clinical_caseMIR	SENT4	-	-
10	,	,	Fc	-	-	232-233	389_QUEST_clinical_caseMIR	SENT4	-	-
11	cHDL	colesterol_hdl	NC00YL0	-	-	234-238	389_QUEST_clinical_caseMIR	SENT4	-	-
12	46	46	Z	-	-	239-241	389_QUEST_clinical_caseMIR	SENT4	-	-
13	mg	mg	NCMN000	-	-	242-244	389_QUEST_clinical_caseMIR	SENT4	-	-
14	/	/	Fh	-	-	244-245	389_QUEST_clinical_caseMIR	SENT4	-	-
15	dL	decilitro	NCMN000	C0439241	calificador	245-247	389_QUEST_clinical_caseMIR	SENT4	-	-
16	,	,	Fc	-	-	247-248	389_QUEST_clinical_caseMIR	SENT4	-	-
17	triglicéridos	triglicérido	NCMP000	C0041004#C0392693	sustancia	249-262	389_QUEST_clinical_caseMIR	SENT4	-	-
18	132	132	Z	-	-	263-266	389_QUEST_clinical_caseMIR	SENT4	-	-
19	mg	mg	NCMN000	-	-	267-269	389_QUEST_clinical_caseMIR	SENT4	-	-
20	/	/	Fh	-	-	269-270	389_QUEST_clinical_caseMIR	SENT4	-	-
21	dL	decilitro	NCMN000	C0439241	calificador	270-272	389_QUEST_clinical_caseMIR	SENT4	-	-
22	,	,	Fc	-	-	272-273	389_QUEST_clinical_caseMIR	SENT4	-	-
23	colesterol	colesterol	NCMS000	C0543421_1	sustancia_1	274-284	389_QUEST_clinical_caseMIR	SENT4	-	-
24	total	total	NCMS000	C0543421_2	sustancia_2	285-290	389_QUEST_clinical_caseMIR	SENT4	-	-
25	220	220	Z	-	-	291-294	389_QUEST_clinical_caseMIR	SENT4	-	-
26	mg	mg	NCMN000	-	-	295-297	389_QUEST_clinical_caseMIR	SENT4	-	-
27	/	/	Fh	-	-	297-298	389_QUEST_clinical_caseMIR	SENT4	-	-
28	dL	decilitro	NCMN000	C0439241	calificador	298-300	389_QUEST_clinical_caseMIR	SENT4	-	-
29	.	.	Fp	-	-	300-301	389_QUEST_clinical_caseMIR	SENT4	-	-

1	¿	¿	Fia	-	-	302-303	389_QUEST_clinical_caseMIR	SENT5	-	-
2	Qué	qué	DT0CN0	-	-	303-306	389_QUEST_clinical_caseMIR	SENT5	-	-
3	actitud	actitud	NCFS000	C0004271	entidad_observable	307-314	389_QUEST_clinical_caseMIR	SENT5	-	-
4	terapéutica	terapéutico	AQ0FS0	-	-	315-326	389_QUEST_clinical_caseMIR	SENT5	-	-
5	le	le	PP3CSD00	C1292157#C0409974	hallazgo#trastorno	327-329	389_QUEST_clinical_caseMIR	SENT5	-	-
6	parece	parecer	VMIP3S0	-	-	330-336	389_QUEST_clinical_caseMIR	SENT5	-	-
7	más	más	RG	C0205172	calificador	337-340	389_QUEST_clinical_caseMIR	SENT5	-	-
8	razonable	razonable	AQ0CS0	-	-	341-350	389_QUEST_clinical_caseMIR	SENT5	-	-
9	?	?	Fit	-	-	350-351	389_QUEST_clinical_caseMIR	SENT5	-	-
10	.	.	Fp	-	-	351-352	389_QUEST_clinical_caseMIR	SENT5	-	-

